share_log

Benchmark Upgrades Emergent BioSolutions to Buy, Announces $5 Price Target

Moomoo 24/7 ·  Mar 7 10:39

Benchmark analyst Robert Wasserman upgrades Emergent BioSolutions (NYSE:EBS) from Hold to Buy and announces $5 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment